CA2927099A1 - Specific anti-cd38 antibodies for treating human cancers - Google Patents

Specific anti-cd38 antibodies for treating human cancers Download PDF

Info

Publication number
CA2927099A1
CA2927099A1 CA2927099A CA2927099A CA2927099A1 CA 2927099 A1 CA2927099 A1 CA 2927099A1 CA 2927099 A CA2927099 A CA 2927099A CA 2927099 A CA2927099 A CA 2927099A CA 2927099 A1 CA2927099 A1 CA 2927099A1
Authority
CA
Canada
Prior art keywords
antibody
pharmaceutical composition
human subject
administered
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2927099A
Other languages
English (en)
French (fr)
Inventor
Antoine Deslandes
Krzysztof J. Grzegorzewski
Marie-Laure Ozoux
Blake TOMKINSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of CA2927099A1 publication Critical patent/CA2927099A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2927099A 2013-10-31 2014-10-31 Specific anti-cd38 antibodies for treating human cancers Abandoned CA2927099A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361898309P 2013-10-31 2013-10-31
US61/898,309 2013-10-31
EP14306220.6 2014-07-31
EP14306220 2014-07-31
PCT/US2014/063380 WO2015066450A1 (en) 2013-10-31 2014-10-31 Specific anti-cd38 antibodies for treating human cancers

Publications (1)

Publication Number Publication Date
CA2927099A1 true CA2927099A1 (en) 2015-05-07

Family

ID=51266255

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2927099A Abandoned CA2927099A1 (en) 2013-10-31 2014-10-31 Specific anti-cd38 antibodies for treating human cancers

Country Status (20)

Country Link
US (2) US20150118251A1 (enExample)
EP (2) EP3063173B1 (enExample)
JP (3) JP2016536314A (enExample)
KR (1) KR20160077155A (enExample)
CN (1) CN106103481A (enExample)
AU (1) AU2014342103B2 (enExample)
BR (1) BR112016009403A2 (enExample)
CA (1) CA2927099A1 (enExample)
CR (1) CR20160186A (enExample)
EA (1) EA035098B1 (enExample)
IL (1) IL245196B (enExample)
MA (2) MA44560B2 (enExample)
MX (1) MX373301B (enExample)
NZ (1) NZ719784A (enExample)
PL (1) PL3063173T3 (enExample)
PT (1) PT3063173T (enExample)
SG (2) SG11201603088RA (enExample)
TN (1) TN2016000142A1 (enExample)
TW (1) TW201522378A (enExample)
WO (1) WO2015066450A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
JP6279065B2 (ja) 2013-03-13 2018-02-14 サノフイ 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
PE20170676A1 (es) 2014-09-09 2017-05-22 Janssen Biotech Inc Terapias de combinacion con anticuerpos anti-cd38
EA202092609A1 (ru) 2014-12-04 2021-10-29 Янссен Байотек, Инк. Антитела к cd38 для лечения острого миелолейкоза
JP7160533B2 (ja) * 2015-05-13 2022-10-25 モルフォシス・アーゲー 多発性骨髄腫（ｍｍ）の処置
CA2986594C (en) * 2015-05-20 2025-06-10 Tufts Medical Center, Inc. Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
HUE051246T2 (hu) 2015-05-30 2021-03-01 Molecular Templates Inc Deimmunizált shigatoxin alegység vázak és azokat tartalmazó, sejthez irányító molekulák
WO2016201337A1 (en) * 2015-06-12 2016-12-15 Immungene, Inc. Engineered antibody-interferon fusion molecules for the treatment of glucose-regulated protein 94 (grp94) expressing cancers
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
HUE053366T2 (hu) 2015-11-03 2021-06-28 Janssen Biotech Inc Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
CN108699161B (zh) 2016-03-04 2022-06-03 莫佛塞斯公司 多发性骨髓瘤中m-蛋白应答的临床评估
CN109641049B (zh) 2016-06-21 2023-07-07 特尼奥生物股份有限公司 Cd3结合抗体
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
EP3484923A1 (en) 2016-07-15 2019-05-22 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
MY200988A (en) 2016-09-14 2024-01-27 Teneobio Inc CD3 Binding Antibodies
KR102745676B1 (ko) 2016-12-21 2024-12-24 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
WO2018237006A1 (en) 2017-06-20 2018-12-27 Teneoone, Inc. Anti-bcma heavy chain-only antibodies
IL312322B2 (en) 2017-06-20 2026-05-01 Teneobio Inc Antibodies against BCMA containing only heavy chains
WO2019031444A1 (ja) * 2017-08-07 2019-02-14 国立大学法人九州大学 細胞集団における特異的結合物質の占有率を測定する方法
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
RU2020112490A (ru) * 2017-09-13 2021-10-13 Тенеобио, Инк. Антитела из тяжелых цепей, связывающиеся с эктоферментами
CN111565751A (zh) 2017-10-31 2020-08-21 詹森生物科技公司 治疗高危多发性骨髓瘤的方法
CN111542545A (zh) 2017-11-03 2020-08-14 索伦托治疗有限公司 Cd38定向嵌合抗原受体构建体
US12371506B2 (en) 2018-01-12 2025-07-29 Takeda Pharmaceutical Company Limited Subcutaneous administration of anti-CD38 antibodies
AU2019244478B2 (en) * 2018-03-28 2025-11-06 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-CD38 antibodies
CA3105333A1 (en) * 2018-07-10 2020-01-16 Sanofi Combination therapies against cancer targeting cd38 and tgf-beta
IL317328A (en) 2018-12-14 2025-01-01 Morphosys Ag Antibody formulations
CA3133419A1 (en) * 2019-03-21 2020-09-24 Gamida Cell Ltd. Expansion and use of expanded nk cell fractions suitable for transplantation in combination therapy
CR20210500A (es) 2019-04-05 2021-11-05 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
JP7665538B2 (ja) 2019-06-14 2025-04-21 テネオバイオ， インコーポレイテッド Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
TW202606756A (zh) 2019-12-05 2026-02-16 美商賽諾菲阿凡提斯美國有限責任公司 用於皮下投予之抗cd38抗體的調配物
IL293615A (en) * 2019-12-06 2022-08-01 Sanofi Aventis Us Llc Use of isatuzimab for the treatment of recurrent and/or resistant multiple myeloma
EP4169949A4 (en) * 2020-06-23 2024-08-21 Jiangsu Kanion Pharmaceutical Co., Ltd. ANTI-CD38 ANTIBODY AND ITS USE
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
US20250382378A1 (en) * 2022-10-31 2025-12-18 Genmab A/S Cd38 antibodies and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
TR199902553T2 (xx) 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CN1976950B (zh) * 2004-02-06 2012-08-29 莫佛塞斯公司 抗cd38人抗体及其用途
EP3312196B1 (en) 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
EP1888647A2 (en) * 2005-05-24 2008-02-20 MorphoSys AG Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
AU2007302448C1 (en) * 2006-09-26 2019-02-14 Genmab A/S Combination treatment of CD38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191841A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191840A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2013059885A2 (en) * 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Polypeptide constructs and uses thereof
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
JP6279065B2 (ja) * 2013-03-13 2018-02-14 サノフイ 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物

Also Published As

Publication number Publication date
PL3063173T3 (pl) 2021-01-11
EA201690905A1 (ru) 2016-08-31
EP3805266A1 (en) 2021-04-14
IL245196A0 (en) 2016-06-30
CN106103481A (zh) 2016-11-09
TW201522378A (zh) 2015-06-16
MX373301B (es) 2020-04-24
MA44560B2 (fr) 2021-01-29
SG10201803288RA (en) 2018-05-30
AU2014342103B2 (en) 2020-06-04
MA44560A1 (fr) 2019-09-30
US20180022814A1 (en) 2018-01-25
MX2016005666A (es) 2016-07-14
PT3063173T (pt) 2020-10-20
NZ719784A (en) 2022-02-25
BR112016009403A2 (pt) 2017-09-19
IL245196B (en) 2021-04-29
EA035098B1 (ru) 2020-04-27
MA44560B1 (fr) 2020-06-30
SG11201603088RA (en) 2016-05-30
JP2016536314A (ja) 2016-11-24
KR20160077155A (ko) 2016-07-01
EP3063173B1 (en) 2020-07-29
TN2016000142A1 (en) 2017-10-06
JP2023109927A (ja) 2023-08-08
EP3063173A1 (en) 2016-09-07
MA39070A1 (fr) 2017-11-30
WO2015066450A1 (en) 2015-05-07
AU2014342103A1 (en) 2016-05-26
US20150118251A1 (en) 2015-04-30
CR20160186A (es) 2016-06-13
JP2025139586A (ja) 2025-09-26

Similar Documents

Publication Publication Date Title
AU2014342103B2 (en) Specific anti-CD38 antibodies for treating human cancers
US20230235060A1 (en) Neutralization of inhibitory pathways in lymphocytes
JP7844558B2 (ja) リンパ球における阻害経路の中和
US20190284294A1 (en) Specific anti-cd38 antibodies for treating human cancers
CN112566937B (zh) 对cd3特异性的抗体及其用途
US12570757B2 (en) Antibodies against the poliovirus receptor (PVR) and uses thereof
TW202402802A (zh) 特異性結合ｃｄ３及／或ｃｄ１２３之抗—ｃｄ３抗體，抗—ｃｄ１２３抗體及雙特異性抗體
EP3092252B1 (en) Antibody targeting cell surface deposited complement protein c3d and use thereof
IL301361A (en) Methods for treating multiple myeloma
US12173081B2 (en) CD19/CD38 multispecific antibodies
AU2017292752A1 (en) Antibodies with low immunogenicity and uses thereof
US20230365714A1 (en) Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
TW202345895A (zh) 在用於治療瀰漫性大型ｂ細胞淋巴瘤之組合療法中針對ｃｄ３和ｃｄ２０之雙特異性抗體
CN113368232B (zh) 多特异性抗原结合蛋白及其应用
HK1223116B (en) Specific anti-cd38 antibodies for treating human cancers
HK40046552B (zh) 对cd3特异性的抗体及其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191030

FZDE Discontinued

Effective date: 20220301